Sector News

Gates invests in Immunocore to spur infectious disease R&D

September 18, 2017
Life sciences

The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to spur research into the use of T cell receptor (TCR)-based therapeutics to treat tuberculosis and HIV.

Immunocore is primarily known for its work in cancer. That is what prompted AstraZeneca, Eli Lilly, GlaxoSmithKline and Roche’s Genentech to strike deals with Immunocore, and what underpinned its $320 million (€268 million) round in 2015. But, while cancer drugs dominate its pipeline from the IND-enabling stage onward, Immunocore’s early-stage teams are also working on autoimmune and infectious disease programs.

Oxford, U.K.-based Immunocore’s infectious disease work has attracted the attention of the Gates Foundation, prompting the world’s largest charitable foundation to invest up to $40 million in the company. Immunocore will use the money to advance programs against tuberculosis and HIV.

Both programs are in preclinical stages, but Immunocore has generated data to support the idea of using TCR-based therapeutics to treat infectious diseases. Last year, Immunocore released in vitro data showing its molecules turn the immune system against HIV-infected CD4+ T-cells, suggesting they may be able to wipe out reactivated HIV reservoir cells.

Immunocore will use some of the Gates Foundation investment to fund R&D into these ImmTAVs, immune-mobilizing monoclonal TCRs against viruses. Another tranche will support work into a related, bacteria-focused class of monoclonal TCRs, ImmTABs, which could orchestrate similar attacks on tuberculosis.

The programs benefit from Immunocore’s work to fuse TCRs to humanized CD3-specific single chain variable fragments to treat cancer.

The investment by the Gates Foundation is reminiscent of others it has made in biotechs. Kymab, another British biotech, and Lodo Therapeutics are among the biotechs to receive investment from the nonprofit. In each case, the involvement of the Gates Foundation has enabled the biotech to apply its drug discovery platform and R&D capabilities to diseases beyond those prevalent in the West that attract investment from traditional VCs, such as cancer.

“We have to find that match where we’re not distracting a company, but we’re actually emboldening and supporting a company by becoming their partner and considering the whole world, not just one sector of the market,” Gates Foundation partner Charlotte Hubbert said last year.

In the case of Immunocore, that means providing a source of earmarked cash and support so the biotech can step up its infectious disease R&D while continuing to advance the cancer programs on which its reputation and prospects rest.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

February 7, 2025

Trump’s tariffs could strain medicine supply and drive drug costs

Life sciences

The last few days have been a rollercoaster for the pharmaceutical industry. Mexico and Canada were bracing themselves for the effects of double-digit tariffs from the US, only for President Donald Trump to pause the levies after striking a deal with the two countries.

February 7, 2025

BD announces intent to separate Biosciences and Diagnostic Solutions business

Life sciences

BD (Becton, Dickinson and Company), a leading global medical technology company, announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation.

February 7, 2025

Jabil acquires CDMO Pharmaceutics International

Life sciences

Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.

How can we help you?

We're easy to reach